# Insurance & Actuarial Review — HOMEDRAW™ Concept Sheet v0.1 Reviewer role: credentialed actuary (FSA/MAAA-equivalent), insurance-regulatory and insurance-asset-management lens. Date: 2026-08-01. Stage: mini-panel review of the successor concept; focus per mandate is the INSTITUTIONAL FUNDING QUESTION — the concept's central bet. Equity Shield sections of my prior charter are moot (the concept deletes it, correctly). Materials: `concepts/HOMEDRAW-CONCEPT.md`; `ANALYSIS.md` §§1, 3, 8; my Stage 1 report (`reviews/insurance-actuarial.md`) and Stage 2 cross-exam (`reviews/crossexam-insurance-actuarial.md`), whose duration and breakeven frameworks are reused and adapted below. All arithmetic recomputed this session in Python (models on file in session scratchpad: `homedraw_model.py`, `homedraw_exits.py`, `homedraw_funding.py`). Standard deal modeled throughout: $625,000 home, $375,000 senior (60% CLTV) at 3.5% (deep-lock vintage; 6.5% variant shown where material), $1,500/mo × 84 months = $126,000 drawn, 9.5% fixed PIK compounding monthly, 7% costs of sale, 30-year legal final. Claim tags: **SETTLED LAW / LIKELY INTERPRETATION / STATE-DEPENDENT / AMBIGUOUS / SPECULATIVE**. Posture: adversarial, as chartered. Where the concept fixes what I killed, I say so — an adversary who cannot concede verified fixes produces noise, not diligence. Three of my Stage 1 kill mechanisms are genuinely cured here; two new defects of comparable seriousness are introduced. Both are quantified below. --- ## 0. Arithmetic integrity of the concept sheet itself (read this first) **Finding 0.1 — The base-case sketch understates its own accrual by ~11%, and every downstream number inherits the error. (MAJOR)** At the sheet's own stated terms ($1,500/mo × 84, 9.5%, compounding monthly), the draw-end balance is **$177,993**, not "≈ $160K" ($168,168 even at annual compounding — no compounding convention produces $160K). Corrected trajectory: | Year | Concept sheet | Correct (monthly comp) | |---|---|---| | 7 (draw-end) | ≈$160,000 | **$177,993** | | 12 (sale example) | payoff ≈$250,000 | **$285,680** | | 13 | ≈$276,000 | **$314,033** | | ~14 ("hits $300K cap") | year ~14 | **year ~12.6** | | 30 (legal final) | not shown | **$1,568,913** | PIK at 9.5% monthly doubles every **7.3 years**. The sheet's year-12 homeowner example overstates the homeowner's net by ~$36K, the Draw-Limit example is mis-timed by ~1.5 years, and — most importantly — the sheet never prints the legal-final balance: **$1.57M owed at year 30 on $126K drawn**. That number drives Findings 4.1–4.3 and must appear in every consumer scenario table the sheet itself mandates (5/10/20/30-yr disclosures). SETTLED (arithmetic on the sheet's own terms). Severity: major — not because the design breaks, but because a funding pitch built on a concept sheet that understates its own asset balance 11% will be re-derived by every warehouse lender and rating analyst, and the sponsor's credibility problem from Equity Flow (investor O3) repeats on day one. --- ## 1. THE SCHEDULE B QUESTION (decisive, per mandate) ### Finding 1.1 — Schedule B reporting is genuinely winnable for directly held ### whole loans; this is the single largest economic fact in the concept. (Supports thesis, with conditions) The statutory-accounting question decomposes into three separate gates the concept sheet compresses into one: **(a) SSAP No. 37 classification (NAIC accounting → Schedule B reporting).** SSAP 37 defines a mortgage loan as a debt obligation that is not a security, secured by a mortgage or deed of trust on real estate, held directly or via participation. There is **no amortization, coupon-frequency, or lien-priority requirement in the SSAP 37 definition**; second liens are reportable on Schedule B, and contractually deferred interest is not "overdue" interest (the good-standing tests key off delinquency versus contract terms, and a PIK loan is performing per its contract). Unlike Equity Flow's ride-along — which I killed on this exact point in Stage 1 FX-A ("an appreciation-contingent, no-maturity claim does not become a mortgage loan by being secured by a deed of trust") — HomeDraw is a true fixed-rate note with a stated maturity, standard security instrument, and no contingent payment. My FX-A objection does not reach it. **LIKELY INTERPRETATION** — with the structural condition that insurers hold **whole loans or true participations**. If they instead hold notes issued by the funding trust, the paper is a security → Schedule D ABS (rated: fine; unrated: dead), and if they hold fund/LP interests, it is Schedule BA. The concept's funding diagram must say "whole-loan / participation private placement," not "insurance private placement," which usually means notes. **(b) RBC factor.** For life insurers, directly held residential mortgage loans in good standing on Schedule B carry a C-1 pre-tax factor of **0.68%** ("residential mortgages — all other"); the residential factor is not LTV-graduated or lien-graduated the way commercial CM categories are. Even the downside cases are mild: a Schedule BA mortgage-character vehicle holding primarily junior liens is CM3 at **3.00%**, and 2024–2026 NAIC actions extended 0.68% look-through treatment to affiliated (2024) and unaffiliated (April 2026) Schedule BA vehicles holding performing residential mortgage loans. The regulatory current is *toward* mortgage-loan look-through, not away from it. **LIKELY INTERPRETATION** on 0.68% for direct holdings; **AMBIGUOUS** whether a PIK-only junior would be pushed to CM-style treatment on examiner challenge — but even that outcome (3.00%) sustains the thesis. **Net-yield arithmetic (9.5% nominal = 9.92% effective annual at full recovery; 10% cost of capital, same convention as my Stage 1 Finding 3.1):** | Treatment | C-1 factor | Capital drag | Net yield | |---|---|---|---| | **Schedule B residential (this concept's claim)** | 0.68% | 0.07% | **9.86%** | | Schedule BA mortgage-fund CM3 (junior-lien downside) | 3.00% | 0.30% | 9.62% | | Stage 1 Equity Flow ride-along (Sch BA other) | 30% | 3.00% | 6.92% | | Stage 1 residual treatment | 45% | 4.50% | 5.42% | **The inversion the concept sheet hypothesizes is real: ~290–440 bps of net yield swings on this classification.** A 9.86% statutory net on a 0.68%-charge asset is not "bond-like return for venture risk" — it is one of the highest capital-adjusted yields available to a life company, which is precisely why gate (c) matters. **(c) State-law admissibility — the gate the concept sheet does not mention. (MAJOR caveat.)** Schedule B reporting and RBC are NAIC constructs; whether the loan is an *admitted asset within the enumerated mortgage class* is state investment law. NY Ins. Law § 1404 permits second-mortgage loans, but its high-LTV residential bucket (up to 90% of value) requires "monthly payments of principal and interest sufficient to repay the loan" within statutory limits — an **amortization test a PIK loan fails by construction**; a non-amortizing junior at up to ~75%+ projected CLTV falls outside the favored bucket and into lower LTV limits or the leeway basket for NY-regulated companies. **STATE-DEPENDENT** — and materially so: it does not kill the thesis (the large annuity buyers are domiciled in IA/AZ/DE/MI-style modernized-code states, and Bermuda-reinsured capital prices under BSCR, not § 1404), but it shrinks the buyer universe and must be mapped domicile-by-domicile before the funding deck claims "insurance bid." **(d) The re-classification tail risk.** NAIC is actively policing HEI-adjacent paper (SAPWG 2025 items tightening what counts as a Schedule BA mortgage fund; the HEI classification debate that motivated this concept's redesign). HomeDraw is distinguishable — no appreciation share, fixed rate, stated maturity — but a first-of-kind PIK consumer junior at scale invites an SVO/SAPWG look, and an adverse interpretive letter mid-fund re-prices every insurer holder from 0.68% to 3–30% overnight. The mitigation is cheap and mandatory: obtain the classification in writing (domiciliary-regulator concurrence and an SSAP 37 opinion from a national statutory-accounting practice) **before** insurer capital closes, not after. **AMBIGUOUS** by nature; manageable. Severity of (c)+(d) combined: **major, not critical** — the first concept in this file where I can write that sentence about the insurance leg. ### Finding 1.2 — What Schedule B does NOT solve: ALM, valuation, and income ### quality. (MINOR-to-MAJOR, buyer-dependent) - **Duration/convexity:** a PIK asset's duration ≈ its exit horizon (13–21 years, Finding 3.1) with mortgage-style negative convexity both directions (refi when rates fall; extension when rates rise, since mobility collapses with rates — my Stage 1 4.1 mechanism, which survives into this product, merely capped now at year 30). Payout-annuity and PRT writers genuinely want 15–20-year duration, so this is a fit for a real buyer segment — but C-3 modeling and cash-flow-testing treatment of a zero-cash asset will haircut the bid. LIKELY INTERPRETATION (practice, not law). - **Statutory income with no cash:** accrual income on Schedule B is admitted, but a book that accretes for a decade produces earnings without distributable cash; asset-adequacy testing will require the insurer to fund liability outflows elsewhere. Insurers cap allocation percentages accordingly. - **Good-standing drift:** RBC does not LTV-test residential loans annually, so the accrual-driven CLTV drift of Finding 4.2 costs the insurer no capital until default — an arbitrage that works until an examiner or SAPWG notices (see 1.1(d)). **Bottom line on Question 1:** PIK + no scheduled payments + junior lien does **not** disqualify the loan from Schedule B under current SSAP 37 for directly held whole loans/participations (LIKELY INTERPRETATION); the realistic factor is 0.68% (downside 3.00%), netting the insurer ~9.6–9.9% — an inversion of my Stage 1 30%/45% arithmetic worth ~290–440 bps. The binding constraints move to state admissibility (STATE-DEPENDENT), ALM fit, and re-classification tail. The concept's central accounting bet is, on current guidance, more right than wrong — it is the first load-bearing funding claim in this file to survive contact. --- ## 2. RATING FEASIBILITY ### Finding 2.1 — Ratability is credible on precedent, but "first to rated ### takeout" is false: the rated precedent for THIS EXACT INSTRUMENT already ### exists and belongs to a competitor. (MAJOR — kills the moat claim, not the funding claim) The concept claims its edge is being "first to rated takeout for this paper." The record says otherwise: - **Finance of America HomeSafe / HomeSafe Second**: proprietary, **non-recourse, fixed-rate, deferred-payment (PIK), second-lien** reverse mortgages — the same instrument as HomeDraw restricted to 55+ — have been securitized repeatedly with **KBRA ratings to AAA** (recent deal: 2,024 loans, ~$106K average balance, 8.30% WA coupon, AAA/AA senior classes). - **Point/Redwood (2021 on) and Unlock HEI securitizations** were rated by DBRS Morningstar **without decades of seasoning**, on a *harder* asset (no stated payments, appreciation-contingent) — via AVM haircuts, stressed-HPA paths, structural credit enhancement, and long trust legal finals. - The **closed-end-second / HELOC rated market** (2023–2026: Rocket, Figure, Saluda Grade programs; DBRS/KBRA/Fitch criteria published) supplies the collateral-file, servicing, and rep-and-warranty template wholesale. So: can this get rated in fund-one's lifetime? **Yes — realistic timeline 3–5 years from first origination**, conditional on (i) ~$150–250M of collateral, (ii) licensed origination and a rated-eligible servicer with backup, (iii) legal opinions on state licensing/usury/reverse-statute capture, (iv) enhancement sized to the crossover stress in Section 4. This is not the year-7-8 fiction of Equity Flow — my Stage 1 3.2 objection was specifically the *absence of a legal final and of any settlement mechanism*; the concept cures the exact defect I named. LIKELY INTERPRETATION (agency practice, precedent-based). But the moat inverts: the precedent that makes HomeDraw ratable makes it **copyable by the incumbent who already owns the rating relationships, servicing stack, and shelf**. FoA extends HomeSafe Second below 62 by changing an underwriting parameter; HomeDraw builds all of it from zero. "First to rated takeout" is not credible; "fast follower into an incumbent's rated market with a CAC thesis" is the honest description, and the funding deck should say so. ### Finding 2.2 — The 30-year legal final is unnecessary for rating and toxic ### elsewhere: the concept solves a problem the precedent shows doesn't exist, ### and buys a new one. (MAJOR) The FoA deals are rated with **no borrower-level stated maturity at all** — the loans are due at death/move-out/sale, and the *trust* carries a distant legal final. The rating problem my Stage 1 3.2 identified was cured by precedent structuring at the trust level, not by putting a balloon in the consumer note. Meanwhile the loan-level 30-year maturity: - **Breaks the Reg Z reverse-mortgage classification the sheet hopes for.** § 1026.33(a)(2) requires that principal and interest be due "**only after**" death, transfer, or cessation of occupancy. A stated 30-year maturity makes the balance due while the borrower is alive and occupying → not a reverse mortgage under Reg Z → the § 1026.43 **ability-to-repay rule applies** to a negatively amortizing, no-income-doc balloon loan — a combination §1026.43 is more or less purpose-built to prohibit. LIKELY INTERPRETATION (regulation text is clear; application untested). Flagged to legal-regulatory, but it is a *funding-design* finding: the maturity exists for ratability, and ratability doesn't need it. - **Guarantees that every loan reaching it is distressed** (Finding 4.3: $1.57M due; homeowner residual $0 at ≤3% HPA; lender impaired ~10% even at trend). An agency models the legal-final bucket at its true recovery; the maturity contributes stress, not comfort. Fix: drop the loan-level maturity (restoring the clean §1026.33 posture and the "due when life settles" promise), keep due-at-death/sale/move-out, and put the legal final where the precedent puts it — on the securitization trust (2060s-style final). This strictly dominates the current design for rating, Reg Z, and consumer optics simultaneously. AMBIGUOUS only in that agencies prefer defined terms all else equal; the FoA precedent shows the preference is not binding. --- ## 3. DURATION / EXIT MODELING AND THE COST OF CARRY ### Finding 3.1 — Rerun of the mobility+mortality model for the new box: ### mean exit 13–15 years (vs ~24 for Equity Flow), 6–10% of loans forced out ### at the legal final in base cases — and 38% in the deep-lock-in tail. (Quantified; severity attaches in 3.2/4.x) Changes from my Stage 1 model: any-age box (modeled at 57 average, 52 for the deep-selection case), lock-in used for *marketing only* (no eligibility gate), **no appreciation-share sale penalty** (Equity Flow's contract added a second lock-in by taxing the sale 25–43% of appreciation; HomeDraw does not — sale merely stops a 9.5% accrual, which is an *incentive* to exit), and a refi channel (the borrower can refinance the accrual away when rates permit). Net: mobility on this book is higher than the Equity Flow book. Hazards: Gompertz mortality (μ(57)≈0.6%, μ(77)≈4.4%) + mobility as tabulated + 0.5–1%/yr refi; 30-year truncation with survivors forced out at legal final: | Scenario | Mean exit | Median | P(>20y) | **P(forced at 30y legal final)** | |---|---|---|---|---| | Unselected mover ~7%/yr, age 57 | 10.0 | 8 | 12.4% | 2.3% | | **Base: self-selected 4.5%/yr, age 57** | **13.2** | **12** | **23.9%** | **6.2%** | | Lock-in marketing works, 3%/yr | 15.3 | 15 | 32.8% | 10.1% | | Deep lock-in 2%/yr, age 52 couple | 21.1 | 25 | 59.3% | **38.2%** | Two structural observations. First, the concept genuinely fixes my Stage 1 4.1 category error: this asset prices off a **fixed accrual**, not off appreciation, so extension no longer destroys value through the discount of a contingent payoff — extension is now ordinary mortgage extension risk, which markets price daily. Second, the marketing self-contradiction survives in softened form: the funnel still *targets* lock-in (low mobility), i.e., markets for duration, while the credit box *needs* early exits (Finding 4.2's drift). The better the lock-in targeting works, the worse Finding 4.3 gets — the deep-lock-in row puts **38% of the book at the legal final owing $1.57M per original $126K drawn**. ### Finding 3.2 — Negative carry: the warehouse phase burns ~$9.6M of cash per ### $100M program before any rated takeout, and the pre-rating capital stack ### does not clear the consumer rate ceiling. (MAJOR) A PIK asset pays the warehouse nothing. Modeling a 794-loan, $100M-commitment book originated over 24 months, warehouse advancing 75% of accrued balance at ~SOFR+300 (7.4% cash): | Year | Book accrued | Warehouse draw | Cash carry (equity-funded) | |---|---|---|---| | 1 | $4.0M | $3.0M | $0.22M | | 2 | $15.8M | $11.9M | $0.88M | | 3 | $32.3M | $24.3M | $1.79M | | 4 | $50.5M | $37.9M | $2.80M | | 5 | $70.4M | $52.8M | $3.91M | | **Cumulative 5-yr cash interest, zero asset cash flow** | | | **$9.6M** | Required asset yield by funding phase (effective-annual build-up: funding + 50bps servicing + 50bps through-cycle credit + 40bps origination amortization + 25–50bps OID/extension premium demanded by holders), against the 9.92% EA the 9.5% coupon delivers at full recovery: | Phase | Blended funding | Required asset yield | Margin vs 9.92% | Implied consumer APR to break even | |---|---|---|---|---| | Warehouse 75/25 @7.4%/16% | 9.55% | **11.25%** | **−132 bps** | **10.35%** | | Rated takeout 85/15 @6.4%/14% | 7.54% | 9.45% | +47 bps | 9.06% | | Insurer whole-loan Sch B (net 7.5% req.) | 7.50% | 9.15% | +77 bps | 8.88% | Read: **at 9.5% the product is underwater by ~130 bps for its entire pre-rating life and clears by only ~50–80 bps after it.** The venture is a bet that ~3 years and ~$10M+ of negative carry per $100M buys entry to takeout economics with a sub-100bp steady-state margin — viable only at scale, only if the rating arrives on schedule, and only if takeout execution matches the modeled 85%+ advance at ≤6.5% weighted coupon. Raising the consumer rate to the 9.75% ceiling adds 25 bps; raising it to cover the warehouse phase (10.35%+) prices above FoA's incumbent product and erodes the consumer thesis. Additionally, rated bonds on PIK collateral either accrete (Z-bond pricing concessions) or depend on prepayment cash, and the reverse-mortgage precedent deals rely on ~3-year call/refinancing structures — the "takeout" is not one exit but a **chain of refinancings across 20+ years**, which jams in 2022-style windows. LIKELY INTERPRETATION (market practice); arithmetic SETTLED on stated assumptions. --- ## 4. CREDIT: THE NON-RECOURSE TAIL ### Finding 4.1 — Adapted breakeven framework: the −27% breakeven of Equity ### Flow becomes a breakeven that MOVES AGAINST THE LENDER ~0.3–0.5pp/yr and ### goes positive at year ~14. (CRITICAL for pricing; the sheet does not price it) Equity Flow's escrow claim was static ($126K), giving a fixed −27.1% breakeven drawdown. HomeDraw's claim compounds at 9.5% against collateral compounding at HPA plus senior amortization. Required home value for full recovery (payoff = balance ≤ V×0.93 − senior), senior at 3.5%: | Exit yr | Balance | Senior | Required V | Breakeven drawdown vs $625K | **Required HPA/yr** | |---|---|---|---|---|---| | 7 | $177,993 | $318,917 | $534,312 | −14.5% | −2.21% | | 10 | $236,422 | $290,351 | $566,423 | −9.4% | −0.98% | | 12 | $285,680 | $269,573 | $597,046 | −4.5% | −0.38% | | 15 | $379,460 | $235,552 | $661,303 | **+5.8%** | **+0.38%** | | 20 | $609,037 | $170,289 | $837,985 | +34.1% | +1.48% | | 25 | $977,510 | $92,565 | $1,150,619 | +84.1% | +2.47% | | 30 | $1,568,913 | $0 | $1,687,004 | +169.9% | **+3.37%** | (6.5%-senior variant: breakevens are uniformly worse — e.g., −11.0% at year 7, +0.76%/yr required at year 15.) The year-7 cushion is roughly **half** of Equity Flow's (−14.5% vs −27.1%) because the claim is $178K rather than $126K and sits behind a larger senior. From year ~14, **any flat-to-down market impairs the loan with zero housing "crash" required**; by the legal final the loan needs **above-trend HPA (3.37%/yr for 30 years) merely to return par**. The 9.5% coupon on the long tail is partially fictional: yield-to-worst, not coupon, is the ratable number. SETTLED (arithmetic). Recovery grid (payoff/balance): | HPA \ exit yr | 7 | 10 | 15 | 20 | 25 | 30 | |---|---|---|---|---|---|---| | +5% | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | | +3% | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 0.90 | | +2% | 1.00 | 1.00 | 1.00 | 1.00 | 0.88 | 0.67 | | +1% | 1.00 | 1.00 | 1.00 | 0.88 | 0.67 | 0.50 | | 0% | 1.00 | 1.00 | 0.91 | 0.67 | 0.50 | 0.37 | 2007-replay paths (peak at origination): national −26.5% trough → recoveries 0.57–0.89 depending on exit year; sand-state −45% → **0.11–0.54**. Unlike Equity Flow there is no escrow-first 1.0x — the entire accrued balance is the junior exposure. Portfolio yield net of these losses (probability-weighted over the Finding 3.1 exit distributions; full-recovery benchmark 9.92% EA): −16 bps at 3% HPA on the base book, −55 to −114 bps at 2%, **−226 to −334 bps at 0%**. The 50 bps through-cycle credit charge in Finding 3.2 is therefore adequate only if HPA ≥ ~2.5% and the deep-lock-in scenario does not materialize; a rating agency will size enhancement off the 0%-HPA and replay rows, not the base case. ### Finding 4.2 — The Draw Limit is calibrated to the wrong variable and stops ### protecting at exactly the moment risk starts compounding. (MAJOR) Two defects: **(a) "Projected CLTV ≤75% at draw-end" is an HPA-assumption artifact.** Actual draw-end CLTV with the corrected $178K balance: 64.6% if HPA = +3%, 74.2% at +1%, **79.5% at 0%, 91.6% at −2%**. A limit computed at closing off a 3% projection binds nothing in the flat/down states where it matters. The "objective number printed in the closing documents" cures the AVM-manipulation findings (genuinely — red-team F1/M1 do not survive), but objectivity was bought by fixing the number in the one dimension (realized HPA) the risk lives in. **(b) The Draw Limit only stops draws; accrual is uncapped for up to 23 more years.** Post-draw, CLTV drifts up ~5–6.5 pp/yr net in a flat market (9.5% on a growing $178K+ balance vs ~$19–27K/yr of HPA+amortization cushion). The instrument that manages this risk in the rated precedent is the reverse mortgage **principal limit factor**: proprietary reverse products advance ~25–40% of value at origination *sized so accrual-to-death rarely crosses 100%*. HomeDraw's combined 75% projected CLTV is roughly double the PLF discipline the rated market imposes on the same risk. What a rating agency will actually require is either (i) a materially lower Draw Limit — solving for 60% projected CLTV at draw-end cuts the draw from $1,500 to ~$1,199/mo; 55% cuts it to ~$875/mo — or (ii) an accrual cap / rate step-down at a CLTV trigger, which reintroduces a contingent term. The consumer product survives (i) in weakened form; the concept sheet has not priced it. LIKELY INTERPRETATION (agency practice); arithmetic SETTLED. ### Finding 4.3 — The legal-final bucket is a designed catastrophe: every ### surviving loan matures impaired, and every surviving homeowner is wiped ### out. (CRITICAL as designed; cured by the Finding 2.2 fix + 4.2 recalibration) At year 30 the balance is $1,568,913. Home value at 3% HPA: $1.52M (net $1.41M) → **lender recovery 0.90 at trend HPA; homeowner residual $0**. At 2.5%: recovery ~0.77, homeowner $0. At 2%: recovery 0.67, homeowner $0. The homeowner's residual hits $0 at roughly year 23 (2% HPA) to year 25+ (3%); "the homeowner keeps 100% of appreciation" is true only for exits before the crossover — for the 6–38% of the book that reaches the legal final, the product consumes the entire house and then forces its sale within a 12-month window. Balance-weighted, this bucket is far larger than its loan count: each legal-final loan carries **8.8x** the draw-end balance. The non-recourse cap converts the homeowner catastrophe into lender severity, so the same cells are simultaneously a UDAAP/headline event (elderly borrower, 30 years of disclosed-but-compounding interest, forced sale, zero proceeds) and a credit loss. No rating committee and no insurer investment committee books this bucket at coupon. The sheet's own #1 open question ("negative amortization is the product") is correct but understated: negative amortization *without a PLF-style cap and with a balloon* is the product. SETTLED (arithmetic); UDAAP characterization AMBIGUOUS but the reputational pricing is not. --- ## 5. VERDICT ON THE FUNDING THESIS — WHO HOLDS THIS PAPER **Buyer map, in order of realism:** 1. **Life/annuity insurers via whole-loan or participation private placements (post-rating-era, and possibly before it):** the real bid. Schedule B at 0.68% nets ~9.6–9.9% — extraordinary on a capital-adjusted basis — and payout-annuity/PRT liabilities want the duration. Constraints: state admissibility mapping (STATE-DEPENDENT, Finding 1.1(c)), allocation caps for zero-cash assets, written classification comfort (Finding 1.1(d)), and a required net yield ~7.5%+ that the 9.5% coupon covers with room. **This buyer exists.** It is the first time in this diligence file that sentence is true. 2. **Rated securitization senior/mezz (banks, money managers):** feasible on the FoA/HEI/CES precedent in 3–5 years at ~6.2–6.5% weighted, 85–90% advance — the takeout the economics require. Accreting-bond and serial-refinancing frictions are real but precedented. 3. **Credit funds (warehouse-phase whole loans / residuals):** will buy at 11–13% required yields — which the 9.5% coupon cannot pay (Finding 3.2). They are bridge capital priced as venture cost, not a hold base. Phantom OID income pushes taxable vehicles toward REIT wrappers (the asset is REIT-qualifying — a genuine structuring asset). 4. **Banks:** no. Basel risk weights on negatively amortizing junior-lien consumer credit plus the 2008 institutional memory of option-ARM/neg-am books close this channel except as warehouse lenders (where they are already modeled). **Does the required yield produce a consumer rate anyone would accept?** Yes — narrowly, and only in the takeout era: the rated/insurer stack requires an asset yield of ~9.15–9.45% EA against the 9.92% the 9.5% coupon delivers, i.e., the consumer rate the capital stack needs (~8.9–9.1% APR steady-state, ~10.35% in the warehouse phase) brackets the 9.5–9.75% the sheet proposes, and 9.5% is market-consistent with the incumbent (HomeSafe Second WA coupon 8.30% plus its 55+/PLF-conservative box). The funding thesis is **not** the fantasy its predecessor's was. Its honest weaknesses are: a ~130 bps-negative, ~$10M-per-$100M warehouse valley; a sub-100 bps steady-state margin; a crossover credit tail the coupon does not price; and a moat claim that is false because the incumbent already owns the rated market. --- ## VERDICT: **FIX-BEFORE-LAUNCH** — and, for the first time in this file, the ## fix list is a fix list rather than a kill in fix costume. What is genuinely cured versus my Stage 1/Stage 2 record: the mortality-vs- mobility category error (fixed accrual replaces contingent appreciation), the no-legal-final rating bar, the Schedule BA 30%/45% capital wall (inverts to 0.68–3.00% for whole loans — LIKELY INTERPRETATION), the Equity Shield unlicensed-insurance exposure (deleted), and the AVM-manipulation surface (deleted). What is not cured or newly created, in required order of repair: 1. **Delete the loan-level 30-year maturity** (Finding 2.2): unnecessary for rating per the FoA precedent, breaks the §1026.33 reverse-mortgage posture and triggers ATR on a neg-am no-doc balloon, and guarantees the Finding 4.3 catastrophe bucket. Trust-level legal final instead. 2. **Recalibrate the Draw Limit to PLF discipline** (Finding 4.2): ~55–60% projected CLTV at draw-end (draw falls to ~$875–1,200/mo) and/or an accrual cap; without it, no rating committee passes the 0%-HPA row and no UDAAP review passes the year-25 homeowner-wipeout cells. 3. **Convert the Schedule B hypothesis into paper before it is load-bearing** (Finding 1.1): SSAP 37 opinion, domiciliary-regulator concurrence, state-by-state admissibility map. The concept's central bet is winnable but currently unwritten. 4. **Re-cut the funding plan around the warehouse valley** (Finding 3.2): ~$10M negative carry per $100M program, three-plus years, before a takeout whose steady-state margin is <100 bps — this is the venture's true capital requirement and it appears nowhere in the sheet. 5. **Fix the sheet's own arithmetic** (Finding 0.1) and restate the moat claim honestly (Finding 2.1): fast follower vs FoA below age 62, competing on CAC and box, not "first to rated takeout." **The single make-or-break number the sponsor must validate:** the **rated takeout execution: ≥85% advance at ≤6.5% weighted bond coupon (blended cost of funds ≤7.55%) achievable within ~36–48 months of first origination.** At that number the 9.5% consumer coupon clears by ~50 bps and every other finding is a repair; 75 bps wide of it (blended ≥8.3%), the required consumer rate exceeds 10.3%, the product loses to the incumbent on price, and the concept fails on the same axis Equity Flow did — not law, but the cost of capital. Validate it the only way it can be validated pre-launch: a rating-agency feasibility engagement (KBRA/DBRS) plus one anchor insurer's written Schedule B classification comfort, both before the first dollar of warehouse draws. --- end of review ---